Page last updated: 2024-12-05

2-methylindole

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

2-Methylindole, also known as skatole, is a naturally occurring heterocyclic organic compound with a strong fecal odor. It is found in feces, coal tar, and some foods. 2-Methylindole is synthesized via the degradation of tryptophan by bacteria in the gut. It has been found to have various biological activities, including antioxidant, anti-inflammatory, and neuroprotective effects. However, it is also associated with negative effects such as unpleasant odor and potential toxicity. Its importance lies in its role as a marker for fecal contamination, and it has been used in environmental monitoring. It is also studied for its potential therapeutic applications, particularly in the areas of neurodegenerative diseases and cancer. '

2-methylindole: SKATOLE refers to 3-methylindole; RN given refers to parent cpd; structure [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

2-methyl-1H-indole : A methylindole that is 1H-indole substituted by a methyl group at position 2. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Cross-References

ID SourceID
PubMed CID7224
CHEMBL ID259419
CHEBI ID49402
SCHEMBL ID12420
SCHEMBL ID377807
MeSH IDM0079688

Synonyms (51)

Synonym
F0290-0682
2-methylindole
2-methyl-1h-indole
1h-indole, 2-methyl-
indole, 2-methyl-
nsc-7514
nsc7514
95-20-5
einecs 202-398-3
nsc 7514
ai3-03945
inchi=1/c9h9n/c1-7-6-8-4-2-3-5-9(8)10-7/h2-6,10h,1h
2-methylindole, 98%
2mi ,
M-3895
STK044221
AC-611
CHEMBL259419
chebi:49402 ,
KUC106612N
ksc-09-215a
methylketole
M0346
AKOS000119568
unii-i7cn58827i
i7cn58827i ,
FT-0613057
FT-0612877
2-methyl indole
AB00375786-04
SCHEMBL12420
CG-0500
DTXSID5059117
SCHEMBL377807
2-methylindol
2-methyl-indole
2-methyl-1-h-indole
methyl indole
STR01200
mfcd00005616
CS-W007556
2-methylindole, purum, >=97.5% (hplc)
2-methylindole, analytical standard
Q4596907
AMY23231
SB14955
2-methyl-1h-indol
NCGC00342152-01
1h-indole, 2-methyl-; indole, 2-methyl- (8ci); 2-methyl-1h-indole; 2-methylindole; nsc 7514
EN300-18136
HY-W007556
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Drug Classes (1)

ClassDescription
methylindoleAny member of the class of indoles carrying one or more methyl substituents.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Bioassays (6)

Assay IDTitleYearJournalArticle
AID1133966Antiulcer activity in po dosed albino rat pyloric ligation model assessed as inhibition of gastric secretion administered as single dose 1 to 24 hrs prior to ligation1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Experimental antiulcer drugs. 1. Indole-1-alkanamides and pyrrole-1-alkanamides.
AID1339469Inhibition of full length PI3Kalpha (unknown origin) assessed as reduction in PIP3 formation at 100 uM using PIP2 as substrate after 45 mins by fluorescence polarization assay relative to control2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Identification of allosteric binding sites for PI3Kα oncogenic mutant specific inhibitor design.
AID329525Activity at androgen receptor ligand binding domain assessed as inhibition of SRC2-3 interaction at 50 uM after 2 hrs by fluorescence polarization assay2007Proceedings of the National Academy of Sciences of the United States of America, Oct-09, Volume: 104, Issue:41
A surface on the androgen receptor that allosterically regulates coactivator binding.
AID1339468Inhibition of wild type PI3K p110alpha/p85alpha niSH2 (unknown origin) expressed in baculovirus infected sf9 cells assessed as reduction in PIP3 formation at 100 uM using PIP2 as substrate after 45 mins by fluorescence polarization assay relative to contr2017Bioorganic & medicinal chemistry, 02-15, Volume: 25, Issue:4
Identification of allosteric binding sites for PI3Kα oncogenic mutant specific inhibitor design.
AID1133965Antiulcer activity in sc dosed albino rat pyloric ligation model assessed as inhibition of gastric secretion administered as single dose 1 to 24 hrs prior to ligation1977Journal of medicinal chemistry, Apr, Volume: 20, Issue:4
Experimental antiulcer drugs. 1. Indole-1-alkanamides and pyrrole-1-alkanamides.
AID656681Inhibition of electric eel AChE using acetylcholine iodide as substrate at 10'-4 M measured every 5 sec for 2 mins by Ellman's method2012Bioorganic & medicinal chemistry letters, Apr-15, Volume: 22, Issue:8
Prospective acetylcholinesterase inhibitory activity of indole and its analogs.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (21)

TimeframeStudies, This Drug (%)All Drugs %
pre-19906 (28.57)18.7374
1990's2 (9.52)18.2507
2000's5 (23.81)29.6817
2010's7 (33.33)24.3611
2020's1 (4.76)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 34.70

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index34.70 (24.57)
Research Supply Index3.14 (2.92)
Research Growth Index4.76 (4.65)
Search Engine Demand Index42.91 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (34.70)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (4.55%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other21 (95.45%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]